Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IVX-A12
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
IVX-A12 is a bivalent, virus-like particle (VLP) vaccine candidate designed to protect against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Developed by Icosavax (acquired by AstraZeneca), the vaccine utilizes computationally designed protein nanoparticle technology originating from the University of Washington. It is intended for older adults, a population at high risk for severe respiratory infections, and aims to be the first combination vaccine to address both pathogens simultaneously. The vaccine is currently Phase III-ready.
- Brand names
- IVX-A12IVX-A-12IVX-A 12
- Other names
- RSV + hMPV combination vaccineRSV/hMPV VLP vaccineinvestigational RSV and hMPV vaccine
02
Targets
hMPV preF (Human metapneumovirus prefusion fusion glycoprotein)RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on IVX-A12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IVX-A12.